Head-to-head GLP-1 provider comparisons built on real all-in monthly cost — advertised starter price vs cost after membership, shipping, dose increases, and prepaid plans. Every figure is labeled verified, secondary, or operator-tracked.
Advertised starter price versus predictable flat-rate cost. NexLife is not always the lowest starter price; these pages show where it is and is not competitive.
| What to know |
|---|
| Head-to-head GLP-1 provider comparisons built on real all-in monthly cost — advertised starter price vs cost after membership, shipping, dose increases, and prepaid plans. |
| Advertised starter price versus predictable flat-rate cost. |
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list; public comments are due by Jun 29, 2026. Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.